The global “infectious disease point of care (PoC) diagnostics“ market size is projected to reach USD 3,371.1 million by the end of 2027. The presence of several large-scale companies in this sector will emerge in favor of market growth. According to a report published by Fortune Business Insights, titled “Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test, Flow-through Test, Molecular Diagnostics, and Others), By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), Influenza, Clostridium Difficile Infections (CDI), Hepatitis C Virus, Methicillin Resistant Staphylococcus Aureus (MRSA), Tuberculosis, and Others), By End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics, Home & Self-Testing, Nursing Homes, and Others), and Regional Forecast, 2020-2027” the market was worth USD 1246.5 million and will exhibit a CAGR of 17.4% during the forecast period, 2020-2027.
Point of care (PoC) testing allows faster diagnosis of diseases at the patient site itself. The drawbacks of conventional diagnostic methods including time to test, inefficiency, and non-portability can be overcome through infectious disease PoC diagnosis. Recent technological advances have opened up a massive potential for the growth of the market in the past few years. The increasing popularity of this concept is consequential to the rapid technological advances. The increasing product demand has encouraged companies to invest higher upfront capital. The sector holds a huge potential for entry-level as well as mid-sized companies across the world. Additionally, increasing research activities will also emerge in favor of market growth in the forthcoming years.
Request a Sample Copy of the Research Report:
List of companies profiled in the report:
- Hoffmann-La Roche Ltd (Basel, Switzerland)
- Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
- Abbott Laboratories (Illinois, U.S)
- Quest Diagnostics Incorporated (New Jersey, United States)
- BD (Franklin Lakes, U.S)
- bioMérieux SA (Marcy l’Etoile, France)
- Cardinal Health, Inc. (Ohio, U.S)
- Mesa Biotech (California, U.S)
- Cepheid (California, U.S)
- Trinity Biotech (Bray, Ireland)
- Quidel Corporation (San Diego, U.S.)
- Bio-Rad Laboratories Inc. (California, U.S)
- Other Players
Industry Developments:
June 2020 – Cepheid announced launch of Xpert Xpress SARS-CoV-2/Flu/RSV a four in one combination test used for the detection of detection of SARS-CoV-2, Flu A, Flu B and RSV from a sample of single patient.
For more information visit : https://www.fortunebusinessinsights.com/infectious-disease-point-of-care-poc-diagnostics-market-104307
Covid-19 Pandemic to Create Massive Opportunities for Rapid Market Growth
The recent coronavirus outbreak has created a sense of panic and urgency across the world. The pandemic has had a drastic impact on several economies across the globe, with SMEs being affected the most. With only large-scale companies being able to sustain the drawbacks of the pandemic in a seamless manner, it is evident that these companies will look to adopt newer strategies to recover the losses in the past few months. The use of several PoC diagnostic test kits has risen dramatically in the past few months, given the ability of the product to generate results in a time span that is lesser than 30 mins. Having said that, major attention has been given to the SARS-Cov-2 infection and other diagnostic products have been kept on hold. As a result, the Covid-19 pandemic has brought mixed fortunes for companies in the infectious disease PoC diagnostics market.
Increasing Product Use during Covid-19 Pandemic will Emerge in Favor of Market Growth
The report encompasses several factors that have contributed to the growth of the overall market in recent years. The massive investments in infectious disease PoC diagnostics have yielded a few exceptional products, enabling applications across diverse treatment procedures. The product has also been put to use in detecting symptoms of Covid-19 in the ongoing pandemic. Several large-scale companies are looking to maximize the use of the product during the pandemic and as a result, the investments in PoC diagnostics has gone up considerably in the past few months. In May 2020, Quest Diagnostics announced that it has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its self-collection antibody test kits. The product is used for test kit for Covid-19 for patients looking to get tested from home. Increasing number of product innovations will have a huge impact on the growth of the overall market in the coming years.
Quick Buy – Infectious Disease Point of Care Diagnostics Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/104307
North America to Emerge Dominant; Growing Penetration of Advanced PoC Diagnostics will Emerge in Favor of Market Growth
The report analyzes the ongoing market trends across North America, Asia Pacific, Europe, the Middle East & Africa, and Latin America. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing adoption of advanced PoC diagnostics, especially in the United States, has contributed to the growth of the regional market. The increasing Covid-19 cases has also given the platform for companies in the infectious disease PoC diagnostics sector. As of 2019, the market in North America was worth USD 457.2 million and this value is projected to rise at a considerable pace in the coming years. The market in Europe held the second largest share, following North America in the global market.
Global Infectious Disease Point of Care Diagnostics Market Segmentation :
By Technique
- Lateral Flow Immunoassay (LFIA)
- Agglutination Test
- Flow-through test/Immunoconcentration Assay
- Molecular Diagnostics
- Others
By Disease
- HIV
- Hepatitis B Virus
- Pneumonia/Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV)
- Influenza
- Clostridium Difficile Infections (CDI)
- Hepatitis C Virus
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Tuberculosis (TB)
- Others
By End User
- Hospital Bedside
- Physician’s Office Lab
- Urgent Care & Retail Clinics
- Home & Self-testing
- Nursing Home
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Have Any Query? Ask Our Experts:
Table Of Content :
- Introduction
- Market Scope
- Market Segmentation
- Market Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Key Infectious Diseases, By Key Countries
- New Product Launches
- Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
- Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
- Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
- Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
- Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
- Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
- Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Technique
- Lateral Flow Immunoassay (LFIA)
- Agglutination Tests
- Flow-through Tests / Immunoconcentration Assays
- Molecular Diagnostics
- Others
- Market Analysis, Insights and Forecast – By Disease
- Human Immunodeficiency Virus (HIV)
- Hepatitis B Virus (HBV)
- Pneumonia / Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV)
- Influenza
- Clostridium difficile infection (CDI)
- Hepatitis C Virus (HCV)
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Tuberculosis (TB)
- Others
- Market Analysis, Insights and Forecast – By End User
- Hospital Bedside
- Physician’s Office Lab
- Urgent Care & Retail Clinics
- Home & Self-Testing
- Nursing Homes
- Others
- Market Analysis, Insights and Forecast – By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Get your Customized Research Report:https://www.fortunebusinessinsights.com/enquiry/customization/infectious-disease-point-of-care-poc-diagnostics-market-104307
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com